Krystal Biotech, Inc. (KRYS) 주식 분석

회사 개요

Krystal Biotech, Inc. operates as a commercial-stage biotechnology enterprise focused on the discovery, development, manufacturing, and commercialization of genetic medicines designed to address high unmet medical needs within the United States healthcare landscape. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry where innovation in genetic therapeutics defines competitive advantage and market positioning. At the time of this analysis, the company demonstrated a significant market capitalization of $7.60B, supported by a trailing twelve-month revenue of $389.13M and an operational workforce of 295 employees. These valuation and revenue metrics indicate that Krystal Biotech commands a substantial market presence relative to typical early-stage biotech firms, suggesting a mature phase of commercialization for its pipeline assets, particularly VYJUVEK. The scale of its market cap relative to its revenue stream implies a high market premium often associated with companies holding proprietary intellectual property in the genetic medicine space.

재무 건전성

The company reported a trailing twelve-month revenue of $389.13M, which generated a net income of $204.83M and an EBITDA of $162.92M, highlighting a robust conversion of sales into earnings before interest, taxes, depreciation, and amortization. The substantial gap between the $389.13M in revenue and the $204.83M in net income reveals a cost structure characterized by exceptionally low operating expenses, allowing the firm to retain a significant portion of its top-line growth as bottom-line profit. Free cash flow stood at $93.93M, indicating strong financial flexibility that enables the company to fund future research and development initiatives or pursue strategic acquisitions without relying heavily on external capital markets. The company maintains a conservative balance sheet with $827.79M in cash reserves against a minimal debt obligation of $9.34M, resulting in a debt-to-equity ratio of 0.77 which suggests low financial leverage. This liquidity position is further underscored by a current ratio of 9.95, signaling an abundance of short-term assets relative to liabilities and ensuring the ability to meet obligations comfortably. Management effectiveness is evidenced by a return on equity of 18.9% and a return on assets of 8.4%, metrics that demonstrate efficient capital deployment and value generation for shareholders. Additionally, the profit margin reached 52.6% while the gross margin was 94.1% and the operating margin was 41.3%, collectively illustrating the high-margin nature of the company's genetic medicine product portfolio.

밸류에이션 평가

Valuation metrics for Krystal Biotech show a trailing P/E ratio of 37.71 compared to a forward P/E of 24.42, implying that the market expects a significant expansion in earnings per share over the coming year that will justify the current high multiple. The price-to-book ratio stands at 6.18, indicating that the stock trades at a substantial premium over its net asset value, a common characteristic for biotechnology firms with valuable intangible assets and patent portfolios. Alternative valuation measures such as a price-to-sales ratio of 19.54 and an EV/EBITDA of 41.33 suggest that investors are pricing in significant future growth potential and successful commercialization of its genetic therapies. Regarding trading range, the stock has reached a 52-week high of $298.30 and a 52-week low of $122.80, providing a context for assessing current valuation volatility within the sector. The beta value of 0.54 indicates that the stock exhibits lower volatility than the broader market, moving with less sensitivity to general market fluctuations compared to high-beta peers. These combined metrics present a valuation profile that balances high current multiples with expectations of substantial earnings acceleration and stable price action relative to the S&P 500.

Growth & Income

Revenue growth over the last year was recorded at 17.5%, while earnings growth achieved 11.6%, indicating that the expansion of the bottom line is proceeding at a slower pace than the growth in top-line sales. This divergence suggests that while the company is successfully increasing its sales volume, it may face some pressure on margins or one-time costs that prevent earnings from growing as rapidly as revenue in this specific period. As a non-dividend payer, Krystal Biotech maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all of its earnings to reinvest into growth initiatives rather than distributing cash to shareholders. This strategic choice to forgo dividends aligns with the typical lifecycle of a biotechnology company that prioritizes capital allocation toward research, development, and manufacturing capabilities to sustain long-term pipeline growth. The overall growth and income profile reflects a capital-intensive growth strategy where the primary source of shareholder value creation is anticipated to come from future earnings expansion rather than current dividend distributions.